Teriparatide (Asubio Pharma)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameTeriparatide (Asubio Pharma)
Drug Alias NameParathyroid hormone (1-34) - Chugai/SuntoryRecombinant human parathyroid hormone[residues 1-34]rhPTH[1,34]Nasal rhPTH(1-34)PTH (1-34) - Chugai/Suntory +[7] 
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionParathyroid hormone receptor agonistsOsteogenesis stimulantsParathyroid hormone replacements
TargetsParathyroid hormone receptor
Therapy Area/IndicationsOsteoporosis, Postmenopausal
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesDaiichi Sankyo Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesChugai Pharmaceutical Co LtdDaiichi Sankyo Co Ltd
Active IndicationsN/A
Inactive IndicationsOsteoporosis, Postmenopausal

Other Information

ATC CodeN/A
Related LinksN/A